tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
AN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience
PremiumRatingsAN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience
2M ago
AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year
Premium
The Fly
AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year
2M ago
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
Premium
The Fly
AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP
3M ago
AN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook
PremiumRatingsAN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook
4M ago
AN2 Therapeutics, Inc.: Promising Future with Strong Financial Health and Strategic Advancements
Premium
Ratings
AN2 Therapeutics, Inc.: Promising Future with Strong Financial Health and Strategic Advancements
4M ago
AN2 Therapeutics reports Q4 EPS (25c) vs (57c) last year
Premium
The Fly
AN2 Therapeutics reports Q4 EPS (25c) vs (57c) last year
4M ago
JMP Securities healthcare analysts hold an analyst/industry conference call
PremiumThe FlyJMP Securities healthcare analysts hold an analyst/industry conference call
6M ago
AN2 Therapeutics downgraded to Hold from Buy at TD Cowen
Premium
The Fly
AN2 Therapeutics downgraded to Hold from Buy at TD Cowen
8M ago
AN2 Therapeutics reports Q3 EPS (43c), consensus (38c)
Premium
The Fly
AN2 Therapeutics reports Q3 EPS (43c), consensus (38c)
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100